UroGen Pharma Stock Forecast - Accumulation Distribution

URGN Stock  USD 11.91  0.36  3.12%   
UroGen Stock Forecast is based on your current time horizon. Although UroGen Pharma's naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of UroGen Pharma's systematic risk associated with finding meaningful patterns of UroGen Pharma fundamentals over time.
  
At this time, UroGen Pharma's Payables Turnover is very stable compared to the past year. As of the 24th of November 2024, Fixed Asset Turnover is likely to grow to 36.80, while Inventory Turnover is likely to drop 0.95. . As of the 24th of November 2024, Common Stock Shares Outstanding is likely to drop to about 17 M. In addition to that, Net Loss is likely to grow to about (93.9 M).
On September 18, 2024 UroGen Pharma had Accumulation Distribution of 59154.21. The accumulation distribution (A/D) indicator shows the degree to which UroGen Pharma is accumulated by the market over a given period. It uses the quote sensitivity to the highest or lowest daily price of UroGen Pharma to determine if accumulation or reduction is taking place in the market. This value is adjusted by UroGen Pharma trading volume to give more weight to distributions with higher volume over lower volume.
Check UroGen Pharma VolatilityBacktest UroGen PharmaTrend Details  

UroGen Pharma Trading Date Momentum

On September 19 2024 UroGen Pharma was traded for  13.85  at the closing time. The top price for the day was 14.57  and the lowest listed price was  13.24 . The trading volume for the day was 986.3 K. The trading history from September 19, 2024 was a factor to the next trading day price boost. The trading price change against the next closing price was 5.73% . The trading price change against the current closing price is 3.44% .
Accumulation distribution indicator can signal that a trend is either nearing completion, at a continuation, or is about to break-outs. The actual value of this indicator is of no significance. What is significant is the change in value of over time. The formula for A/D of a given trading day can be expressed as follow: ((Close - Low) - (High - Close)) / (High - Low) X Volume
Compare UroGen Pharma to competition

Other Forecasting Options for UroGen Pharma

For every potential investor in UroGen, whether a beginner or expert, UroGen Pharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. UroGen Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in UroGen. Basic forecasting techniques help filter out the noise by identifying UroGen Pharma's price trends.

View UroGen Pharma Related Equities

 Risk & Return  Correlation

UroGen Pharma Technical and Predictive Analytics

The stock market is financially volatile. Despite the volatility, there exist limitless possibilities of gaining profits and building passive income portfolios. With the complexity of UroGen Pharma's price movements, a comprehensive understanding of forecasting methods that an investor can rely on to make the right move is invaluable. These methods predict trends that assist an investor in predicting the movement of UroGen Pharma's current price.

UroGen Pharma Market Strength Events

Market strength indicators help investors to evaluate how UroGen Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading UroGen Pharma shares will generate the highest return on investment. By undertsting and applying UroGen Pharma stock market strength indicators, traders can identify UroGen Pharma entry and exit signals to maximize returns.

UroGen Pharma Risk Indicators

The analysis of UroGen Pharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in UroGen Pharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting urogen stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.

Pair Trading with UroGen Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if UroGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with UroGen Stock

  0.68ME 23Andme HoldingPairCorr
  0.89VALN Valneva SE ADRPairCorr
  0.68JNJ Johnson Johnson Sell-off TrendPairCorr

Moving against UroGen Stock

  0.62KZR Kezar Life SciencesPairCorr
  0.4MLYS Mineralys Therapeutics,PairCorr
  0.33MDGL Madrigal PharmaceuticalsPairCorr
The ability to find closely correlated positions to UroGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace UroGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back UroGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling UroGen Pharma to buy it.
The correlation of UroGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as UroGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if UroGen Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for UroGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock:
Check out Historical Fundamental Analysis of UroGen Pharma to cross-verify your projections.
To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.02)
Revenue Per Share
2.389
Quarterly Revenue Growth
0.209
Return On Assets
(0.21)
Return On Equity
(14.81)
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.